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ABSTRACT
Methamphetamine (METH) abuse impacts the global economy through costs associated
with drug enforcement, emergency room visits, and treatment. Hyperthermia is a leading cause
of METH induced emergency room visits and may lead to neural damage. Previous research has
demonstrated early life stress, such as childhood abuse, increases the likelihood of developing a
substance abuse disorder. However, the effects of early life stress on neuronal damage induced
by chronic METH administration are unknown. We aimed to elucidate the effects of early life
stress on METH induced dopamine damage in the striatum. Animals were separated three hours
per day during the first two weeks of development or 15 minutes for control. In adulthood, rats
received either a subcutaneous 0.9% saline or 5.0 mg/kg METH injection every two hours for a
total of four injections. Rectal temperatures were taken before the first injection and one hour
after each subsequent injection. Seven days after testing, rats were euthanized and striatum
was collected for quantification of tyrosine hydroxylase (TH) and dopamine transporter (DAT)
content by Western blot. METH significantly elevated core body temperature in males and
decreased striatal DAT and TH content and this effect was potentiated by early life stress.
Females did not exhibit an effect of METH except in the elevated heat condition in the
preliminary study, which significantly decreased DAT levels. We further ran a preliminary study
looking at early life stress, METH dosing in adulthood during ambient (22-23°C) or elevated (2730°C) temperature .Preliminary results indicated a replication of experiment one with no effect
of elevated temperatures. These studies indicate maternal separation increases METH induced
damage in males, and females are less susceptible to METH induced damage.
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CHAPTER I
INTRODUCTION
METH use and abuse leads to daily societal issues. In subsequent pages the
effects of METH will be described on an economic, societal, organismal, and molecular
level. METH affects not only individuals using or abusing the drug but also families, law
enforcement, and society. Over the past ten years many steps have been taken to
alleviate these issues, but many problems persist today. Persistent problems associated
with METH and other illegal drug use warrants a great deal of research to improve
societal and individual problems. Identifying early warning signs and assisting at-risk
populations remains a beneficial realm of study.
The need to understand the molecular and behavioral factors behind METH use
and its effects has escalated as awareness of such problems has increased. As the METH
problem propagates, more research is required to adequately address the variety of
issues associated with acute and chronic METH use. Chronic METH use results in longterm neurological and behavioral deficits. These deficits occur primarily in dopaminergic
and serotonergic neurons and in specific regions of the brain and are associated with
several other markers of neuronal damage. The following will explain the biological and
behavioral deficits associated with chronic METH use in clinical and preclinical studies.
This research aimed to characterize the effects of early life stress on METH
induced neural damage. Study one examined the effects of repeated maternal
separation, a model of early life stress, on METH induced dopaminergic neural damage
in adulthood. Since elevated hyperthermia drastically affects the extent of neural
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damage, study two examined the effects of early life stress on methamphetamine
induced dopamine damage at elevated environmental temperatures.
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CHAPTER II
CLINICAL DRUG USE AND METHAMPHETAMINE INDUCED DAMAGE

Methamphetamine Use and Abuse in Human Populations
Many amphetamines, such as d-amphetamine, methamphetamine (METH), and
3,4-methylenedioxymethamphetamine (MDMA), are used and abused as recreational
drugs. Although dangers are associated with the overuse and abuse of all these
substances, there is an increased concern for methamphetamine. METH is typically
smoked in a dose-binge pattern, making the usage more dangerous relative to damphetamine, and more instances of neural damage have been observed in individuals
who abused METH, rather than d-amphetamine or MDMA (reviewed in Gouzoulis-May
& Daumann, 2009).
The typical route and pattern of administration for METH are unique among the
amphetamines, leading to higher risk of cellular damage with METH use. Damphetamine and MDMA are typically taken orally as pills whereas METH is typically
smoked, leading to faster absorption and distribution and, consequently, rapid effects
on the body and brain. Individuals who abuse METH take the drug in a dose-binge
pattern, comprised of multiple doses over the course of 4 to 24 hours. This pattern of
use leads to elevated blood plasma levels of METH which can lead to subsequent
damage observed in human METH abusers (Cho, Melega, Kuczenski, & Segal, 2001).
When this pattern of administration is modeled in animals, it produces significant
reductions in the density of striatal dopamine terminals (see section II. C.).
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Methamphetamine (METH) use and abuse remain continual problems in the
United States and around the world. In 2010, the worldwide rate of amphetamines
abuse was estimated between 0.3-1.2percent, second only to cannabis abuse (United
Nations Office of Drugs and Crime, 2012). Over the past decade, the United States and
several countries throughout the European Union increased penalties for making,
selling, and distributing METH. Due to these increased penalties and subsequent man
power directed towards METH trafficking, rates of METH use have begun to stabilize
and, in some cases, slightly decrease throughout the U.S. and the world. However, rates
of METH distribution and use have risen in other Asian, South American, and African
countries. Although some areas of the world have been successful in diminishing
distribution and use of METH, METH use persists at problematic levels throughout the
world and United States.
METH is a growing problem in several countries, likely due to its ease of
production relative to other amphetamines. METH is easily synthesized from
pseudoephedrine by using common household items and readily obtained recipes from
online sources. The United States, as well as countries in the EU, recently started
enforcing laws limiting the sale of pseudoephedrine. However, pseudoephedrine is now
smuggled into the United States in bulk for later distribution to METH laboratories.
Additionally, the amounts of illegal METH coming into the United States from Mexico
and other countries have increased over the past decade, which leads to increased
funding required for drug enforcement (Cunningham et al., 2010).
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The elevated use of METH over the past twenty years has contributed to
increased economic burdens associated with illegal METH production, sales, and abuse.
The production of METH occurs in homemade laboratories, which contain many harmful
chemicals. These chemicals may lead to explosions and destruction of property.
Additionally, the costs associated with cleaning and disposal of seized METH labs
accounts for several millions of dollars spent yearly. Illegal imports, mainly from Mexico,
of both METH and pseudoephedrine account for millions of dollars of border
enforcement and DEA funding. Finally, the costs associated with emergency room visits,
drug associated crimes, and drug treatment therapy accounts for billions of dollars
annually (NIDA, 2010; Bureau of Justice, 2011). The economic burden associated with
illegal METH production, distribution, and abuse remains a main issue in the United
States.
Aside from the economic burdens, METH creates multiple problems on an
individual level. Acutely, METH elevates body temperature resulting in increased risk of
hyperthermia. Over half of all stimulant induced emergency room visits occur due to
complications associated with elevated body temperature (NIDA, 2010). Furthermore,
METH use often accompanies risky sexual behavior which puts individuals at an
increased risk for contracting a sexually transmitted disease. This is particularly true for
risk of HIV infection among homosexual men, a group in which METH use is more
prevalent than in the general population (NIDA, 2008). Several health risks are
associated with acute use of METH, adding to negative consequences already associated
with the drug.
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METH can also lead to several chronic physical health problems. Elevated heart
rate during METH intoxication increases the risk for stroke due to hypertension (Ho et
al., 2009). METH abuse of more than five years can lead to dopamine depletions
(discussed in section B), resulting in symptoms similar to Parkinson’s disease. These
symptoms may be reversible, but recovery of normal motor activity can take several
years (Callaghan, Cunningham, Sajeev, & Kish, 2010). Finally, long term use of METH can
lead to dental decay (Hamamoto & Rhodus, 2009). Acutely, METH use causes a decrease
in saliva production, similar to the dry mouth side effect of ADHD medications with
amphetamine. Decreased salivary production increases the chance of plaque
development. METH use also causes dehydration, and sugary drinks are commonly
drunk by people who use METH. Individuals on a METH “run” or “binge” typically stay
up for several hours and exhibit poor oral hygiene; METH also leads to bruxism and
trismus which augment the oral deficits associated with METH use (Hamamoto &
Rhodus, 2009). These factors combined lead to an increased rate of dental problems in
individuals who abuse METH. Although direct evidence that METH causes dental decay
is lacking, a higher rate of dental decay is observed in individuals who abuse METH.
Chronic mental health problems also persist in individuals who have abused
METH for several years. Acute use of METH is associated with the onset of a first
psychotic episode in individuals with family histories of schizophrenia. Long-term abuse
of METH, anywhere from one to seven plus years, can lead to METH-induced psychosis,
similar to that of schizophrenia including hallucinations, delusions, disorganized
thought, and social withdrawal (Grelotti et al., 2010). Although these effects appear to
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dissipate with time, the symptoms may reappear several years after abstinence from
METH (Sato, Chen, Akiyama, & Otsuki, 1983).
Numerous deficits in cognitive function have also been demonstrated in
individuals who have met the criteria for METH dependence for at least five years (Scott
et al., 2007). Problems with working memory and recall were observed in patients who
met the criteria for METH dependence and had been abstinent for 30 days (Johnason et
al., 2006). Individuals also exhibit deficits in attention and working memory tasks for up
to six months after maintaining abstinence (McKetin & Mattick, 1997). Some cognitive
deficits, such as poor performance in the Wisconsin-card sorting task, appear to recover
with long-term abstinence (over a year) but the extent of impairment is often correlated
with the duration and frequency of use (Volkow et al., 2001).

Neural Changes Associated with Methamphetamine Use and Abuse in Humans
Multiple studies indicate several neural differences in the brains of chronic
methamphetamine users and controls. Human studies show deficits in post mortem
tissue samples as well as living patients via various imaging techniques. These
differences remain fairly stable even after several months of abstinence.
Post mortem studies indicate decreased dopamine functioning in the brains of
METH abusers. Wilson et al. (1996) examined the brains of deceased patients who
previously met the criteria for substance dependence and died from causes unrelated to
METH or other drug use. METH use was associated with significantly decreased levels of
the dopamine transporter (DAT), tyrosine hydroxylase (TH), and dopamine in the
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caudate putamen and nucleus accumbens relative controls that did not use METH or
other drugs of abuse. DOPA decarboxylase and vesicular monoamine transporter
(VMAT) protein levels did not vary between brains of METH users and age-matched
controls, suggesting, METH may not lead to terminal damage but a decrease in
expression of DAT and TH, depending on the duration and pattern of use. Other markers
of neural damage have also been identified. Relative to matched controls, increased
markers of oxidation were identified in the caudate nucleus and prefrontal cortex of
individuals who met the criteria for METH dependence and had METH in their system at
the time of death, suggesting oxidation occurs in humans which may be a result of
METH administration (Fitzmaurice et al., 2006). Finally, looking at METH users who
previously met criteria for substance dependence and had METH in their system at time
of death, Kish et al. found decreased serotonin transporters in the prefrontal cortex and
occipital cortex (Kish et al., 2009). These studies suggest METH may decrease dopamine
terminals in areas of the striatum and serotonin terminals in areas of the cortex.
However, chronic METH use may simply decrease expression of these proteins rather
than leading to terminal damage.
Magnetic resonance spectroscopy (MRS) studies indicate cellular damage and
decreased function in METH users. Long term METH users (met criteria for substance
abuse) showed decreased markers of cellular integrity and function one year after
abstinence. Specifically, lower ratios of N-acetyl aspartate (NAA) to creatine (CR) were
observed in the frontal cortex and basal ganglia of recovering METH users relative to
control patients (Ernst et al., 2000). Small NAA/CR ratios and low NAA are associated
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with neuronal loss, decreased neuronal function, and disease states. A follow up study
showed similar decreased NAA/CR ratios correlated with cognitive impairments and
extent and frequency of METH use (Sekine et al., 2002). Finally, decreased NAA was
observed in recovering METH patients diagnosed with HIV, and this pattern did not
occur in matched HIV positive controls (Chang et al., 2005). These studies indicated
reduced cellular function in abstinent METH abusers.
Positron emission tomography (PET) imaging studies indicate similar findings to
the previously mentioned structural imaging in the brains of individuals who met the
criteria for METH dependence relative to controls. PET studies indicate decreased
dopamine transporters and D2 receptors in the striatum of one-month abstinent METH
abusers. The extent of these deficits correlated with cognitive performance in that the
greater the dopaminergic deficits, the worse individuals performed on cognitive tasks
(Volkow et al., 2001a; Volkow et al., 2001b). METH abusers also show decreased
metabolism in the prefrontal cortex at rest relative to control subjects. Decreased
resting metabolism correlated with decreased performance in the Wisconsin Card
Sorting task, a task highly dependent on prefrontal function (Volkow et al., 2001a).
These studies indicate decreased markers of dopamine terminals associated with
decreased performance in cognitive tasks. Based on these observations, it has been
hypothesized that chronic METH use causes deficits in dopamine systems, which, in turn
affect cognitive ability. The exact mechanisms of how dopamine deficits lead to
decreased cognitive abilities remain widely unknown and need further study.
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As with most human studies, several confounds exist. One glaring issue remains
in determining a cause and effect relationship. Little clinical evidence exists indicating
the structure and function of the brain of individuals before beginning drug use. Some
of these findings may have been present before initiation of drug use and contributed to
developing an addiction. Altered dopamine functioning occurs in many other disorders,
such as attention deficit hyperactivity disorder (ADHD). Low doses of psychostimulants
reduce symptoms of ADHD, such as cognitive deficits and inattention. Individuals with
ADHD, or other dopamine associated disorders, may start self medicating with
stimulants, eventually leading to the development of an addiction (Lakhan, Shaheen,
Kirchgessner, & Annette, 2012). However, never-medicated patients with ADHD exhibit
increased dopamine transporters in the caudate nucleus, suggesting the underlying
dopaminergic variations in these disorders do not account for METH-induced changes.
Although preclinical studies have made great strides in determining mechanisms for the
observed deficits, we cannot examine in vivo effects of chronic METH use in drug-naïve
humans. Therefore, it remains a challenge to determine the extent of neuronal damage
caused by METH abuse.
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CHAPTER III
MECHANISMS OF METHAMPHETAMINE INDUCED NEURAL DAMAGE

Mechanisms of Action of Methamphetamine
Researchers categorize methamphetamine as an amphetamine with two main
isomeric forms. The l-enantiomer exhibits relatively low efficacy and is commonly mixed
with the more efficacious d-isomer in therapeutic compounds. The d-enantiomer
exhibits the highest efficacy and appears as a colorless powder or crystal (Mendelson et
al., 2006). Illicit METH may appear dirty or yellowish due to its impurities and the
process by which it was made (Cho, 1990). METH is sold legally in Europe as a mix of the
l- and d-enantiomers for its therapeutic effects to treat ADHD. METH is also sold as a
treatment for obesity and is an effective weight loss drug, likely due to its appetite
suppressant effects (Schifano, Corkery, & Cuffolo, 2007). METH is readily soluble in
water and may be consumed orally, intravenously, through mucus membranes, or
smoked. METH reaches peak plasma levels around an hour after administration and has
a half life of 7-8 hours (Cook, et al., 1993). METH is broken down hepatically and is
excreted mainly in its original form. About 5-15% of METH is converted into
amphetamine which acts as an active metabolite (Caldwell, Dring, & Williams, 1972).
Physiologically, METH stimulates the central and sympathetic nervous systems,
which contribute to its therapeutic effects (Schneider, 1972). Acutely, METH elevates
heart rate and blood pressure, increases respiration, dilates bronchia, decreases gut
motility, and decreases salivary production (Kiyatakin et al., 2007). Acute administration
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of METH also increases release of cortisol, the main stress hormone in humans, and
elevated levels are observed several hours after administration of the drug (Harris et al.,
2003).
METH exerts its biochemical effects on the monoamines: dopamine, serotonin,
and norepinephrine. METH is lipophilic and readily crosses the blood brain barrier to
enter the brain and reach its target proteins. In vitro studies indicate METH affects
membrane bound dopamine transporters by binding to the same site as dopamine and
reverses the proton gradient to pump dopamine into the synaptic cleft (Sulzer et al.,
2005). Although METH likely interacts with norepinephrine and serotonin transporters
in the same way, this has yet to be demonstrated. Moderate concentrations of METH
can also lead to the internalization of the dopamine transporter leading to a reduction
in the cell’s ability to remove dopamine from the synaptic cleft (Li et al., 2010). Elevated
levels of norepinephrine and serotonin are also observed at the synapse level after the
administration of METH, however, the role of METH in dopamine release has been the
neurotransmitter studied extensively. Interesting, METH releases norepinephrine to the
greatest degree, followed by dopamine, and finally serotonin to the least degree (Han
and Gu, 2006). Although METH has the greatest effect on norepinephrine, long-term
effects on dopamine systems are more commonly observed relative to norepinephrine
systems (Kish, 2008). Possible reasons for this effect will be discussed in section III C.
The chemical structure of METH, allowing for its high lipophilicity, allows METH
to enter presynaptic terminal buttons through monoamine transport proteins or directly
across the cell membrane (Mack & Bonisch, 1979). Intracellularly, METH interacts with
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the vesicular monoamine transporters (VMATs), transport proteins which normally
sequester cytosolic monoamines into synaptic vesicles. METH interacts with this protein
to decrease the amount of monoamines taken into synaptic vesicles, thereby increasing
the amount of monoamines in the cytosol (Fleckenstein, Volz, & Hanson, 2009). It is also
thought that METH may reverse the proton gradient of the vesicular monoamine
transporter and spill monoamines into the intracellular space (Partilla et al., 2006).
However, the effect of reverse transport of VMATs by METH occurs at very high
concentrations and has yet to be demonstrated at doses taken by typical METH abusers.

Animal Models of Methamphetamine Use
Clinical populations indicate several long lasting pharmacodynamic and cognitive
changes associated with METH use. Clinical self-report data, as well as imaging and
behavioral studies, have revealed several effects of acute and chronic METH use.
However, human studies remain limited in fully understanding the cellular mechanisms
which contribute to the effects of short term and long term METH use. Much of the
research regarding molecular mechanisms of METH has been clarified with the aid of
animal studies in primates and rodents. Rodents are easier to obtain and have shorter
life spans relative to primates; therefore, the majority of studies have been performed
on rodent models. This section focuses mainly on results from rodent studies. Rodent
models of METH use fall into two main categories: acute effects of METH administration
and chronic effects of METH administration. These areas of study examine behavioral,
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neurochemical, and cognitive effects predisposing animals to self-administer METH and
the effects after METH administration.
Studies of acute METH administration largely examine the neurobiological
mechanisms of drug reward and factors contributing to METH self-administration.
Several studies have observed the immediate increase in extracellular monoamines
throughout the brain following METH administration. Dopamine release in the nucleus
accumbens occurs once METH has entered the brain, rapidly after administration. This
release is associated with the rewarding properties of METH as measured by selfadministration and conditioned place preference. Blocking dopamine release in the
nucleus accumbens diminishes METH induced drug reward indicating the involvement
of this circuit in the rewarding effects of METH (reviewed in Sulzer, Sonders, Poulson, &
Galli, 2005).
Since METH is a widely abused substance and may cause cognitive and neuronal
deficits, much of the preclinical research has focused on effects of long term
administration of METH rather than acute effects. Both primate and rodent studies,
mainly rodent, have attempted to determine what neural and cognitive deficits occur
due to repeated METH administration, whether these deficits are long-term or if they
are recoverable, and more recently, what are the factors contributing to the observed
deficits. Many of these early studies directly looked at behavior after high doses not
resembling human equivalents. More recently, acute effects of METH are being
determined using self administration studies rather than researcher administration or
conditioned place preference measurements (Kraemer & Maurer, 2002).
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Early studies focused on neural systems and neural deficits associated with
METH administration. Many of these studies found damage to serotonin and dopamine
systems. The damage observed lasted for several years and never fully recovered.
However, one major issue with these studies was the large doses of METH used over
short periods of time. The pattern of dosage and volume administered was not
representative of METH use in humans. Early studies gave large bolus injections, such as
two injections of 25.0 mg/kg METH (a very high dose), and looked at dopamine and
serotonin markers days to weeks after administration (Seiden, Fischman, & Schuster,
1976). This approach did not allow for adequate comparisons to human populations.
Early research in animal models used high doses of METH as a model of
Parkinson’s disease. Parkinson’s disease is a neurodegenerative disorder characterized
by extensive loss of dopamine neurons in the substantia nigra that project into the
striatum. High doses of METH, well beyond those observed in human populations, lead
to extensive and irreversible neurotoxic damage to dopamine neurons (Perez-Reyes et
al., 1991). Early research utilized this knowledge and used METH as a model of
Parkinson’s disease by injecting rodents or primates with large doses of METH, either
subcutaneously (S.C.) or directly into the brain. These bolus doses lead to extensive
dopamine cell death and specific Parkinson-like motor behavioral phenotypes. Motor
deficits and neuronal damage have been very well documented, however, METH is no
longer accepted as an appropriate model of Parkinson’s disease for one key reason.
METH use may lead to Parkinson’s like motor deficits in human subjects and animal
models because METH affects dopamine neurons. However, extensive METH use leads

15

to degeneration of dopamine axon terminals that may be somewhat reversible after
several years of abstinence (Sonsalla, Jochnowitz, Zeevalk, Oostveen, & Hall, 1996).
Parkinson’s disease destroys entire dopamine neurons, rather than the terminal damage
observed after long term METH administration. Although similar behavioral phenotypes
exist between Parkinson’s disease and extensive METH dosing, the cellular mechanisms
appear to affect dopamine neurons differently. Importantly, several markers of METH
induced damage are observed regardless of development of Parkinson’s disease
symptomologies.
More recently, studies focus on dose regimens similar to those observed in
human users. As stated earlier, human uses administer METH in a dose-binge pattern.
This usage pattern allows for elevated blood plasma levels of METH due to continual
administration before METH is fully metabolized. The elevated METH plasma levels are
thought to contribute to long-term neuronal effects. Animal models attempt to mimic
the dosage pattern of humans by giving small to moderate doses of METH (1.0mg/kg7.5mg/kg) during short windows of time (every two hours), roughly equivalent to those
which occur in humans.

Markers of Neural Damage in Animals
Several METH induced neural changes occur in clinical populations of those
individuals who have met the criteria for METH dependence. Similar deficits are
observed in animal models following four to five doses of 3.0mg/kg-10.0mg/kg METH
administration. Researchers began to examine the effects of METH on the central
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nervous system in the 1970s, mainly in rodents and primates. With advanced imaging
technology, human subjects corroborated many of the observed deficits. METH affects
dopamine, norepinephrine, serotonin, glutamate, neuronal metabolism, and neuronal
signaling.
Early studies on primates indicated decreased markers of monoamines and
overall neuronal function after METH administration. After several high doses of METH
(25.0-50.0mg/kg), rhesus monkeys and rodents exhibit decreased dopamine and
serotonin levels in areas of the cortex (Seiden, Fischman, Schuster, 1976; Wagner et al.,
1980). Decreased serotonin and dopamine synthesis rates were also observed in areas
of the cortex and striatum. Synthesis rates were determined by examining the amount
of rate-limiting enzymes (tryptophan hydroxylase and tyrosine hydroxylase), decreased
serotonin and dopamine content in the cortex and striatum, and overall decreased
dopamine turnover in the striatum and prefrontal cortex (Gibb & Kogan, 1979;
Hotchkins, Morgan, & Gibb, 1979; Seiden, Commins, Vosmer, Axt, & Marek, 1988;
Wagner et al., 1980). Decreased dopamine transporters and serotonin transporters
were also observed after acute administration of METH (Ricaurte et al., 1982; Seiden,
Commins, Vosmer, Axt, & Marek, 1988). Studies which looked at the lasting effects of
METH indicate many of these deficits occur several months, even years (at least 7), after
cessation from METH (Ricaurte et al., 1982; Johnson, Hanson, & Gibb, 1989; Brunswick,
Benmansour, Tejani-Butt, & Hauptmann, 1992). These studies indicate METH results in
significant decreases in markers of serotonin and dopamine systems, which can persist
long term.
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Although decreased markers of serotonin and dopamine systems are observed
after METH dosing, it is difficult to conclude that METH leads to neurotoxic effects on
dopamine terminals. Acutely, METH can cause intracellular sequestration of dopamine
transporters for 24-72 hours (Kahlig & Galli, 2003; Fleckenstein, Metzger, Wilkins, Gibb,
& Hanson, 1997). This effect stems from METH’s direct effect on dopamine transporters
in that the transporters are briefly sequestered in the cytoplasm to counteract the
METH-induced over activity. Chronic METH dosing can additionally lead to decreased
gene expression of the dopamine transporter. Decreased dopamine transporters likely
lead to an inability of the neuron to remove dopamine from the synapse after increased
dopamine release. This effect likely potentiates METH’s effect on synaptic terminals (Xie
et al., 2002). The effect on serotonin is largely uncharacterized, but likely is affected by
similar mechanisms (Haughey, Brown, Wilkins, Hanson, & Fleckenstein, 2000).
Additional markers of synaptic integrity and synaptic structure support the idea
that METH causes neuronal damage. Administration of both low (4.0mg/kg) and high
doses (10.0mg/kg) of METH results in the degenerations of axon terminals in the
nigrostriatal pathway. Silver staining techniques indicate terminal degeneration in the
striatum of rodents after 4 doses of 4.0mg/kg METH (Ellison & Switzer, 1993). This effect
is observed in a range of doses (3.0mg/kg-10.0mg/kg), is accompanied by elevated
microglia activation, and is potentiated in elevated temperatures (Bowyer et al., 1994;
Broening, Pu, & Vorhees, 1997; O’Callaghan & Miller, 1994). Different than the
degeneration observed in Parkinson’s disease, METH affects dopaminergic nerve
terminals and leaves midbrain cell bodies intact, except in the case of extremely high
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doses (Sonsalla, Jochnowitz, Zeevalk, Oostveen, & Hall, 1996). These studies suggest
decreased dopamine markers are likely a result of terminal degeneration rather than
decreased rate of protein synthesis or intracellular sequestration.
Early studies mainly focused on the damaging effects to dopamine systems in the
striatum, but, more recently similar effects on terminal degeneration are observed in
non-dopaminergic cortical regions. Degeneration of serotonin terminals is observed in
areas of the frontal cortex after two administrations of 10.0mg/kg METH (Commins, Axt,
Vosmer & Seiden, 1987). Aside from the observed serotonin degeneration, other cell
types and areas of the cortex undergo terminal degeneration after METH
administration. Using Fluoro-Jade staining, Eisch, Schmued, and Marshall (1998)
observed decreased neuronal integrity in the somatosensory cortex after 4 injections of
4.0mg/kg every two hours. Additionally, several studies went on to demonstrate
damage in the somatosensory cortex is observed several months after an increasing
METH regimen and is potentiated during times of elevated temperatures and the
production of reactive oxygen species (O’Dell & Marshall, 2000; O’Dell & Marshall, 2002;
O’Dell & Marshall, 2005). The degeneration in cortical regions not only affects serotonin
and dopamine terminals but occurs in several other cortical neurotransmitter systems
including glutamatergic and GABAergic neurons (Eisch, O’Dell, & Marshall, 1996; Eisch &
Marshall, 1998).
These studies indicate METH administration has profound effects on several
neurotransmitter systems. METH not only alters dopamine signaling but has altered
norepinephrine, serotonin, glutamate, and general cell signaling. The extensive effects
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of acute and chronic METH administration indicate a vast array of cellular effects which
alter brain activity both short and long-term.

Contributing Mechanisms
METH administration leads to several acute and chronic effects. Extensive
administration (more than 6 months of use in humans, 4 moderate injections in animals)
of METH results in decreased markers of dopamine systems which persist for months to
years after abstinence. Morphological and neurochemical studies indicate these deficits
occur at the cellular level and are not only changes in transcription or translation.
Several mechanisms contribute to the deficits observed after METH administration.
Several studies support the following mechanisms’ contribution to METH induced
damage: hyperthermia, oxidative stress, excitotoxicity, and, more recently, DNA
damage, apoptosis, and microglia activation (see appendix for a summary of these
effects).
Elevated body temperature, or hyperthermia, contributes greatly to the deficits
observed after METH dosing. Alone, hyperthermia does not cause damage to dopamine
systems. Rather, hyperthermia occurs as a result of multiple injections of METH.
Elevated core body temperatures correlates with decreased dopamine transporters in
the striatum of animals that received 5.0 mg/kg METH every 2 hours for 8 hours
(Bowyer et al., 1994). Further elevating body temperatures during 4.0 mg/kg x 4 doses
METH leads to enhanced damage to terminals in the striatum (Tata, Raudensky, &
Yamamoto, 2007). Inhibiting hyperthermia during METH dosing attenuates damage to
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dopamine and serotonin systems (Bowyer et al., 1994; Ali, Newport, & Slikker, 1996;
Bowyer & Ali, 2006). Finally, compounds which exhibit protective effects against METH
lower body temperature, but when core body temperature is elevated through
environmental manipulations, these substances do not have beneficial effects. This
suggests the effects of these compounds are likely due to their ability to attenuate a
hyperthermic response rather than directly alter the effects of METH (Bowyer et al.,
1994). These studies indicate core body temperature is a main mediator of METH
induced neural damage. Controlling for hyperthermia attenuates METH induced damage
but does not completely save these deficits. Some studies demonstrated neuronal
deficits independent of hyperthermia, suggesting other factors aside from hyperthermia
contribute to the long term effects of METH.
METH leads to increased dopamine release in the cytoplasm and synaptic
terminal. Excessive amounts of dopamine leads to auto oxidation and the formation of
reactive oxygen species. The excessive amount of reactive oxygen species produced
burdens scavenger systems which lead to oxidative stress. Depleting dopamine before
METH administration attenuates dopamine deficits in the striatum (Axt, Commins,
Vosmer, Seiben, 1990; Seiden, Commins, Vosmer, Axt & Marek, 1988). Increasing
dopamine availability before METH administration greatly increases damage to
dopamine and serotonin systems in the striatum and cortex (Schmidt et al., 1991).
Dopamine availability plays an important role in METH induced dopamine and serotonin
damage which is likely due to auto-oxidation of dopamine leading to the overproduction
of free radicals and oxidative stress.
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METH not only leads to elevated monoamine release but increased firing of
glutamate neurons (Abekawa, Ohmori, & Koyama, 1994; Stephens & Yamamoto, 1994).
High glutamatergic activity, or extensive firing of one type of neuron, leads to increased
intracellular calcium from extracellular space and mitochondria. Elevated intracellular
calcium levels have several damaging effects to neurons and may lead to excitotoxicity
and eventual death of the cell through several mechanisms. Blocking glutamate release
after METH leads to protective effects to dopamine terminals in the striatum but not
complete attenuation of damage to dopamine systems (Sonsalla, Albers, & Zeevalk,
1998; Sonsalla, Nicklas, & Heikkila, 1989). The effects of glutamate release on METH
induced damage also occur independently of temperature and oxidative effects (Bowyer
et al., 1994; Chipana, Torres, Camarasa, Pubill, Escubedo, 2008; Sonsalla, Riordan, &
Heikkila, 1991). Extensive glutamate release likely contributes to the long term effects of
METH on dopamine and serotonin systems but is not the sole mechanism of neuronal
damage.
Evidence also suggests METH administration causes several other effects which
contribute to cellular damage. METH administrations leads to microglia activation
immediately following a dose, and microglia remain active for up to three days after
METH cessation (Asanuma, Tsuji, Black, & Itzhak, 1999; LaVoie, Card, & Hastings, 2004).
Microglia are part of the brain’s immune response and become active after damage
occurs in the brain. Thus, it is likely that METH administration induces cellular damage.
The role of microglia in METH induced terminal damage remains unclear, but likely aids
in cellular repair and damage immediately after METH administration (Thomas & Kuhn,
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2005; Sriram, Miller, O’Callaghan, 2006). However, it has also been suggested that
microglia contribute to neuronal damage. Other mechanisms by which METH-induced
damage may occur include intracellular DNA damage are observed in dopamine neurons
one week after METH administration (Jayanthi, Deng, Noailles, Ladenheim, & Cadet,
2004). Additionally, activation of several apoptotic pathways occurs directly after METH
administration (Deng et al., 2002). Activation of these pathways likely results from
damage to DNA, dysfunction of the endoplasmic reticulum due to reactive oxygen
species, and dysfunction of the mitochondria due to elevated intracellular calcium levels
(Cadet, Jayanthi, & Deng, 2003; Cadet, Jayanthi, & Deng, 2005; McCullough, Martindale,
Klotz, Aw, & Holbrook, 2001). Additionally, hyperthermia likely potentiates these effects
(Brown & Yamamoto, 2003). These emerging mechanisms likely play important roles in
the basis of METH induced cellular damage.
METH induces cellular damage to dopamine and serotonin neurons through the
interactions of several mechanisms. DNA damage, activation of apoptotic pathways, and
microglia activation hours to days after METH administration indicates cellular distress.
Markers of this damage include decreased dopamine and serotonin terminals,
compromised neural integrity via degraded structural components, and lower dopamine
and serotonin content. This damage remains stable for at least seven days after METH
cessation. This damage occurs through the contributions of METH induced
hyperthermia, oxidative stress, and exitotoxicity. However, the degree and role these
mechanisms play in METH induced neuronal damage is not fully understood.
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CHAPTER IV
STRESS AND DRUGS OF ABUSE

Neural Systems of Stress
External and internal stressors activate biological stress systems including the
sympathetic nervous system and hypothalamic-pituitary-adrenal (HPA) axis. Various
stressors activate these systems to equip the organism to handle subsequent acute and
chronic stressors (McEwen, 2007; Tsigos & Chrousos, 2002). The extent of activation of
these systems depends on the frequency and duration of the stressor (Levine, 2000).
The effects of stress vary on an individual basis based on prior history, fitness, and
extent of the stressor. In general acute, brief stressors tend to show mild benefit for the
organism whereas chronic, prolonged stress or multiple stressors tend to show
detrimental effects.
The physiological stress response consists of two main aspects, sympathetic
nervous system activation and HPA-axis activation. In mammals, the presence of one or
many stressors immediately activates the sympathetic nervous system. This activation
happens within seconds and prepares the body to face the stressor or readies it to flee
(Selye, 1936). The body releases epinephrine from the core of the adrenal glands which
elevates heart rate, dilates pupils and air ways, and increases breathing rate. Endocrine
signals are released shortly after activation of the sympathetic nervous system (Habib,
Gold, & Chrousos, 2001). The hypothalamus releases corticotrophin releasing factor
(CRF) in the anterior pituitary which releases adrenocorticotropin hormone (ACTH) into
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the peripheral circulation. ACTH further signals the cortex of the adrenal glands to
secrete the body’s main stress hormone, cortisol in humans and corticosterone in
rodents. Cortisol, or corticosterone, further prepares the body to deal with the stressor,
chiefly by mobilizing glucose. Once released, cortisol binds to glucocorticoid receptors in
the hippocampus and hypothalamus to signal the termination of this response. These
two responses occur after the onset of a stressor and the duration and frequency of the
activation depends on the duration of the stressor, the number of stressors, and prior
histories (Selye, 1936).

Clinical Evidence of Stress and Drugs of Abuse
A physiological system tries to maintain homeostasis (or set point), however,
with prolonged exposure to specific stimuli, this set point may reset. The physiological
stress response aids in maintaining homeostasis and proves to be beneficial for the
organism unless activated chronically or at multiple time points throughout the life
history of the organism. Exposure to minor stressors for short periods of time aids in the
regulation of the stress response and may be beneficial. Exposure to chronic or
cumulative stressors alters the homeostatic set point and may be detrimental to the
organism. A history of multiple, major life stressors is associated with several
detrimental health effects. These deficits include decreased immune functioning,
elevated heart rate, and insulin resistance. Research in humans indicates individuals in
high stress careers and those who report higher amounts of cumulative life stressors
show an increased risk of cardiac disease, type II diabetes, depression, and immune
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disorders (McEwen, 2007). Elevated heart rate and respiration likely contribute to the
elevated risk of heart disease and stroke, whereas increased glucose mobilization
contributes to increased risk of type II diabetes.
Stress additionally increases an individual’s sensitivity to drugs of abuse,
increases the susceptibility of developing a substance use disorder, and contributes to
maintaining an addiction. Higher rates of alcohol use and abuse occur in high stress
rated careers relative to less stressful careers, while controlling for socio economic
status (Brown, Vik, Patterson, Grant, & Schuckit, 1995). Individuals with histories of
early life stress, such as childhood abuse or a diagnosis of PTSD, have a nineteen times
higher likelihood of developing a substance abuse disorder (Dube et al, 2003; Saxon et
al., 2001). These studies indicate life histories of stress are a risk factor for drug abuse.
Stress further contributes to the maintenance of substance use disorders. Individuals
diagnosed with a substance use disorder report relapsing to drugs of abuse during times
of high stress (Kreek & Koob, 1998; Sinha, 2001). After an acute stressor, recovering
cocaine addicts report more drug cravings relative to non-stressed controls (Volkow et
al., 2002). These findings suggest stress influences the susceptibility, development, and
maintenance of substance abuse.

Preclinical Evidence of Stress and Drugs of Abuse
Both acute and chronic stress interact with mechanisms of drugs of abuse.
Although clinical evidence supports this claim, much of the knowledge elucidating
neural mechanisms has occurred in animal models. Models of drug sensitivity, drug
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reward, and drug craving indicate an effect of both acute and chronic stressors in
relation to drugs of abuse.
Animal models indicate mild stress may be moderately beneficial by decreasing
the rewarding properties of drugs of abuse, but chronic stress is detrimental. Relative
to controls which received no manipulations, rats previously exposed to mild stressors,
such as exercise, showed decreased conditioned place preference scores for
amphetamine and morphine, suggesting mild stress may attenuate the rewarding
properties of these drugs (Papp, Muscat, & Wilner, 1993; Valverde, Smadja, Roques,
Maldonado, 1997). On the other hand, chronic, noxious stressors, such as foot shock,
increased conditioned place preference scores for amphetamine and morphine relative
to rats which did not receive any stress, suggesting chronic stress enhances the
rewarding properties of these drugs (Will, Watkins, & Maier, 1998).
Rodents exhibit increased sensitivity to the initial rewarding properties of drugs
of abuse after being exposed to a chronic stressor. Drug self administration is a
common measure of drug reward in that animals are trained to press a lever to receive
a drug infusion. Animals will self administer almost all drugs of abuse, including
nicotine, opiates, cocaine, amphetamine, and methamphetamine. Rats acquire drug
self administration more quickly when exposed to an acute stressor prior to training,
suggesting an increased sensitivity to the rewarding and addictive properties of drugs
of abuse (Kitanaka & Takemura, 2003; Robinson & Berridge, 2001). Rats also acquire
amphetamine self administration more quickly after previous exposure to chronic
stressors (Maccari et al., 1991). After exposed to an acute stressor, such as foot shock,
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rats self administer more cocaine relative to those not exposed to stress (Ahmed &
Koob, 1997). These studies indicate both acute and chronic stressors decrease
acquisition time and elevate the amount of drug self administered.
Acute and chronic stressors also lead to reinstatement of drug seeking behavior.
Drug self administration can be extinguished after multiple pairings of the original lever
press with saline. Drug seeking behavior may be reinstated through injections of the
original drug or exposure to stressors. Rats resume lever pressing for cocaine after
extinction if given an acute stressor, suggesting stress increases drug seeking behavior
in animal models (Ahmed & Koob, 1997). Chronic stressors, including intermittent
random stressors and food deprivation, also lead to reinstatement of lever pressing
and conditioned place preference for cocaine (Erb, Shaham, & Stewart, 1996; Lu, Liu, &
Ceng, 2001). Finally, pharmacological chronic stress which induces immune system
activation leads to reinstatement of methamphetamine lever pressing (Shepard,
Shaham, & Morales, 2011). These studies indicate acute and chronic stress plays a role
in drug seeking behaviors.
HPA-axis activation appears to play a critical role in the effects of stress on drug
reward. Acute use of drugs leads to activation of the HPA-axis and several stress
hormones are associated with drug seeking behavior. Pretesting corticosterone levels
correlate with the amount of cocaine self administered (Carroll, 1985). Injecting
glucocorticoids into adrenalectomized rats leads an enhanced sensitivity to the
rewarding properties and locomotor activation properties of amphetamine (Deroche et
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al., 1995). Blocking the release of corticotrophin releasing factor attenuates stress
induced cocaine reinstatement (Shaham, Erb, Leung, Buczek, & Stewart, 1998).
The above studies indicate both behavioral and physiological cross sensitivity
between stress systems and drugs of abuse. Additionally, stress early in life alters
regulatory stress and reward systems leading to increased drug sensitivity.
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CHAPTER V
ANIMAL MODELS OF EARLY LIFE STRESS

Paradigms
Early life stress greatly increases an individual’s susceptibility to developing a
substance use disorder. Children who are physically abused are nineteen times more
likely to develop an addiction relative to non-abused children of the same
socioeconomic status (Dube et al., 2004). Although this pattern emerges within clinical
data, the underlying biological mechanisms remain unknown. Development of the HPAaxis occurs during the first two weeks of post natal development in rodents, analogous
to the third trimester of fetal development in humans. The presence of the dam inhibits
the stress response and her absence activates the HPA-axis (De Kloet, Rosenfeld, Van
Eekelen, Sutanto, & Levine, 1988). Because of the mediating activity of the dam during
this critical period, her prolonged absence results in continual activation of the HPA-axis.
This prolonged activation leads to long term biological alterations which persist into
adulthood (Vazquez, 1998). Three categorical animal paradigms used this concept to
model early life stress in humans: maternal deprivation, maternal separation, and social
isolation.
Maternal deprivation was one of the first procedures to attempt to emulate
early life stress. Maternal deprivation removes the pups from the dam for a 24 hour
period during the first week of development (Levine, 1988). Control litters are left with
the dam. This paradigm was among the first developed and tested cognitive tasks and
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sensitivity to opiates in adult animals. Maternal deprivation impedes physical growth,
leading to deficits in weight gain in deprived groups. This model is no longer widely
used, as it is impossible to attribute behavioral outcomes to the early life stress itself,
rather than delayed physical development.
Maternal separation has replaced maternal deprivation as the more common
paradigm. Using the same principles, these procedures separate pups from the dam for
anywhere from one to six hours a day during the first week or two weeks during postnatal development. Separated litters do not exhibit stunted growth, but do exhibit
distinct behavioral phenotypes in adulthood (Meaney, Brake, & Gratton, 2002). These
effects are described in depth in the following section.
Stress does not have to occur during the first two weeks of post natal
development to have long term effects. Social isolation studies the effects of stress
during adolescence. Immediately after weaning from the dam, around post natal day 23,
rats are housed in individual cages or pair housed as a control group. Isolated rats
remain individually house throughout adolescent development until adulthood, around
post natal day 60. Adult rats exhibit similar behavioral characteristics as maternally
separated rats in that they exhibit anxiety-like behaviors (Lapiz et al., 1999). However,
socially isolated also exhibit minor deficits in working memory and prepulse inhibition
and therefore is typically used as a model for schizophrenia (Varty et al., 2000;
Wilkinson et al., 1994).
Physiological, behavioral, and cognitive deficits occur after extensive lengths and
durations (more than 1 hour per day for at least one week) of early life stress. This
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indicates prolonged activation of the HPA-axis during critical stages of development
leads to long term effects which persist into adulthood. These models allow us to better
elucidate the effects of early life on long term development.

Behavioral Effects of Maternal Separation
The effects of prolonged stress during development lead to distinct behavioral
phenotypes in adulthood, similar to problems observed in the clinical population.
Human studies indicate early childhood stress is associated with several disorders,
including depression, anxiety disorders, and substance use disorders. Animal studies
indicate similar behaviors in that animals that have undergone early life stress show
behaviors associated with despair, anxiety, and increased vulnerability to drugs of
abuse.
Animals who underwent early life stress exhibit signs of anxiety and despair.
Relative to controls, maternally separated animals exhibit decreased struggle time in the
forced swim task and the tail suspension task, two model of despair (Aisa, Tordera,
Lasheras, Del Rio, & Ramirez, 2007; Aisa, Tordera, Lasheras, Del Rio, & Ramirez, 2008).
Separated animals also fail to escape in a learned helplessness task, indicative of
depressive-like symptoms (Vollymayr & Henn, 2001; Chen et al., 2001). Separated rats
also exhibit anxiety-like behaviors in adulthood. Separated animals display increased
freezing behavior and hyperactivity in response to a novel environment (Caldji, Francis,
Sharma, Plotsky, & Meaney, 2000; Kalinichev et al., 2002). In an elevated plus maze task,
separated rats spend more time in the closed arms compared to controls (Aisa et al.,
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2007). These depressive- and anxiety- like responses are similar to human studies which
suggest early life stress is a risk factor for developing several disorders, including
depression and anxiety disorders (Sadowski, Ugarte, Kolvin, Kaplan, & Barnes, 1999).
Aside from depressive- and anxiety- like symptoms, early life stress leads to
sensitivity to the behavioral effects of drugs of abuse. Separated animals exhibit
increased sensitivity to analgesic effects of morphine along with increased pain
sensitivity after withdrawal from morphine (Vazquez, Giros, & Dauge, 2006). Separated
animals show increased sensitivity to the locomotor activating effects of acute cocaine
and amphetamine (Kikusui et al., 2005; Matthews, Hall, Wilkinson, & Robbins, 1996).
However, separated animals do not exhibit long term locomotor sensitization to
amphetamine across a range of doses (Brake et al., 2004; Weiss et al., 2001). This effect
may have been due to procedural differences or suggest early life stress may affect the
acute locomotor sensitivity but does not affect sensitivity long term. Additionally,
separated animals may be maximally sensitized due to the effects of early life stress,
such that they are unable to develop further sensitization to multiple amphetamine
injections. Interestingly, early life stress sensitizes animals to the acute locomotor
effects of METH at low and medium doses, which additionally may indicate an acute
sensitivity rather than a long term effect (Pritchard, Hensleigh, & Lynch, 2012). These
studies suggest early life stress has varying effects on sensitivity to behavioral effects of
several drug classes.
A large field of evidence additionally supports the role that early life stress
increases sensitivity to the rewarding properties of drugs of abuse. Separated animals
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will self administer more morphine and spend more time in a chamber paired with
morphine relative to controls (Herman & Panksepp, 1978). The acute rewarding
properties of cocaine reward are additionally affected by early life stress. Cocaine selfadministration is acquired more rapidly and at lower doses in separated animals relative
to controls (Kosten, Miserendino, & Kehoe, 2000; Moffett et al., 2006). Separated
animals further show sensitivity to the rewarding properties to an acute injection of
amphetamine by increased electrical activity in the nucleus accumbens (Der-Avakian &
Markou, 2010). However, early life stress did not alter METH reward in a conditioned
place preference paradigm (Faure, Stein, & Daniels, 2011). One reason we might see
increased sensitivity to the locomotor, but not the rewarding effects of METH may be
that stress differentially affects systems underlying these two behaviors. However,
several studies demonstrate early life stress sensitizes animals to the rewarding
properties of other drug classes.

Neural Changes
Several neural alterations occur as a result of early life stress. These changes
occur in several regions of HPA-axis function as well as dopamine systems. These
neuronal alterations likely underlie the behavioral deficits observed in these animals.
Early life stress alters the physiological response to stress. Separated animals do
not differ from controls in terms of basal circulating levels of the stress hormones:
adrenocorticotropin hormone (ACTH) and corticosterone. After an acute stressor,
separated rats show higher release of ACTH and corticosterone relative to control
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animals, indicating a potentiated stress response (Aisa, Tordera, Lasheras, Del Rio, &
Ramirez, 2008; Lippmann, Bress, Nemeroff, Plotsky, & Monteggia, 2007). Separated
animals also show prolonged elevated levels of stress hormones after an acute stressor
indicating deficits with negative feedback shut-off of the HPA-axis (Aisa et al., 2007; Aisa
et al., 2008). Additional studies indicate decreased glucocorticoid receptor density in the
hippocampus of separated animals. These receptors are important for mediating the
negative feedback signal (Plotsky et al., 2005). This decrease was likely an effect of
prolonged activation of these receptors by heightened levels of corticosterone during
the maternal separation procedure. In adulthood, separated rats exhibited increased
mRNA CRF levels in the paraventricular nucleus indicating a possible compensatory
mechanism due to the elevated stress hormone levels (Plotsky et al., 2005). Early life
stress modifies many aspects of the HPA-axis including activation, release, and
deactivation. These effects likely underlie many of the behavioral deficits observed in
adult rats, such as depressive like symptoms and anxiety.
Dopamine systems are heavily tied to the rewarding and sensitizing effects of
drugs of abuse and early separation greatly alters these systems. Separated animals
show decreased dopamine transporter and D3 receptor mRNA and protein levels, as
well as increased stress-induced dopamine release, in the nucleus accumbens (Brake et
al., 2004; Meaney et al., 2005). Furthermore, increased dopamine release was observed
in the nucleus accumbens after cocaine administration. These combined effects likely
underlie the enhanced rewarding properties of drugs due to increased dopamine in the
synaptic cleft and a decreased reuptake capacity. Post synaptic changes also occur.

35

Separated animals display increased D1 and D2 receptors in the nucleus accumbens,
likely as a compensatory mechanism due to elevated dopamine levels (Moffett et al.,
2006). Although it is clear early life stress alters reward circuits, it remains unclear
exactly how this occurs. It likely results from interactions with the over activation of the
HPA-axis during development, but is not well characterized.
A large body of research supports the role of early life stress in altering stress
and reward circuits. Several behavioral alterations are observed in these animals which
are likely due to these long term biological changes. However, to fully understand early
life stress’ function in behavior changes, further research is required. The alterations in
dopamine systems may affect susceptibility to METH induced damage, however, this
effect has yet to be examined in the maternal separation model.
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CHAPTER VI
RATIONALE AND HYPOTHESES
METH use may result in long-term neuronal and cognitive deficits which may be
potentiated by stress. In the same regard, early life stress is a major risk factor for
developing a substance abuse disorder. Animal models indicate early life stress leads to
sensitivity to drugs of abuse, including METH. It is likely early life stress alters several
neurological circuits which may result in an increased susceptibility to METH induced
neuronal damage. The studies aimed to characterize the effect of early life stress on
METH induced dopamine damage in the striatum.
In the first study, separated or control rats received four injections of 5.0mg/kg
METH over a period of eight hours in adulthood. Temperature was monitored before
the first injection and one hour after every METH injection. The striatum was dissected
out one week after the METH dosing for protein quantification of dopamine
transporters (DAT) and tyrosine hydroxylase (TH). A low to moderate dose of METH was
chosen to detect between group effects and avoiding a ceiling effect. It was
hypothesized METH would elevate core body temperature but not above strokeinducing levels (40°C). Two markers of dopamine neurons were selected to determine
the effects of METH on dopamine function. METH leads to down-regulation of DAT,
which contributes to terminal damage due to the decreased ability to remove dopamine
from the synaptic cleft. It was hypothesized that in METH treated rats, early life stress
would lead to decreased levels of DAT and TH relative to control litters.
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The second preliminary study examined the effects of early life stress on METHinduced dopamine damage at elevated temperatures. Study two was similar to study
one except another group of elevated temperature rats were tested (see methods for
more in-depth description). METH use commonly occurs in settings with elevated
temperatures, such as raves, and METH abusers typically do not monitor their
temperature unless they require medical attention. Additionally, early life stress may
lead to problems with thermoregulation. This may occur due to impaired function of
HPA-axis and immune system function. Since hyperthermia is commonly associated with
METH use and is a main contributor to METH induced neuronal damage, it is vital to
understand early life stress’ impact on these effects. In study two, it was hypothesized
that early life stress would decrease DAT and TH in the striatum and this effect would be
potentiated by elevated temperatures.
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CHAPTER VII
METHODS

Experiment 1
Breeding
A total of eighteen Long-Evans breeding rats (Harlan) were pair housed by same
sex and allowed a one week habituation to the facility before breeding. Breeding pairs
were used for both studies. Breeding pairs were housed together in hanging wire cages
and monitored for the presence of a vaginal plug for up to five days. Pairs were
separated upon visualization of a vaginal plug and returned to plastic tub cages. Males
were returned to their same sex cage mate and females were moved to a single cage
and monitored for pregnancy. If no plug was present after five days, pairs were
separated and later paired with a different mate. Pregnant females remained
untouched except for cage changes until birth of the litter. A total of 148 rats
(experiment 1 = 90; experiment 2=56) derived from 14 litters of 10-12 pups, were used
in the studies.
Separation
Separation and control procedures began after birth. The day of birth was
designated post natal day (PND) 0 and litters remained untouched until the next day. On
PND 1, the pups were sexed and either fostered or culled to roughly equal litter sizes.
Fostered pups were rolled in the cage bedding of a litter born within one day of the
original birth litter and monitored for aggressive behavior from the foster dam. Litters
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underwent pseudo-random assignment into a control or separated groups to achieve
roughly equal numbers for each group. During PND 2-14, control litters were removed
from the dam and weighed, with this procedure lasting approximately fifteen minutes
each day. Separated litters were removed from the dam, weighed, and individually
separated in plastic containers for three hours per day during PND 2-14. Separated pups
stayed on a heating pad, maintained at a constant temperature of 32°C, and were
checked every 30 minutes for signs of hyperthermia or hypothermia. After the three
hour separation period, pups were returned to the dam. Identification of individual pups
occurred by use of a non-toxic pen until PND 6-7, at which point ear punches were used
for identification. Pups remained untouched, except for weekly cage changes, with the
dam during PND 15-20. Weaning of pups occurred on PND 21, at which time pups were
weighed and housed in same sex pairs. Starting on PND 40, pups were handled daily
until the start of testing between PND 60-70. A total of 56 rats were used in the
preliminary study.
Methamphetamine Dosing
Methamphetamine hydrochloride (Sigma-Aldrich, St. Louis, MO) was dissolved in
sterile 0.9% saline at a concentration of 5.0mg/ml (expressed as salt weight). Between
PND 60-70 animals received saline or methamphetamine (METH) injections over an
eight hour period. Core body temperature measurements were taken every two hours
starting between 8:00am-8:30am. A thermocouple probe (Fluke) was inserted
approximately five to six millimeters into the rectum for five to ten seconds to obtain
baseline temperature. Rats then received one subcutaneous injection of 5.0mg/kg
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METH or 0.9% saline (1.0ml/kg) every two hours for a total of four injections. Rectal
temperatures were taken one hour after every injection of saline or METH. If the core
body temperature exceeded 40°C, animals were cooled by use of a washcloth and ice
until core body temperature dropped below 39°C, at which point no further injections
were given and rats were monitored for the remainder of the day. After the final
temperature measurement, rats were returned to their home cages and left
undisturbed for seven days. After seven days, rats underwent euthanasia by anesthetic
overdose of Somnasol (390 mg pentobarbital and 50 mg phenytoin). The brain was
dissected out and the striatum was collected by use of a rodent brain matrix and a
0.3mm micropunch. Tissue samples were placed in Eppendorf tubes and immediately
placed on dry ice, followed by storage at -80°C until quantification by Western Blot.
Sacrifice seven days after METH administration was selected to determine the effects of
MS on terminal damage as opposed to acute regulation of dopamine systems. METH
acutely leads to the sequestration of DAT in the cytosol 24-72 hours after METH
administration, but levels return to normal after this time period (Kristopher, Kahlig &
Galli, 2003). Taking brain tissue seven days after METH administration gave an accurate
picture of METH’s enduring effects on dopamine systems.

Experiment 2
All procedures occurred as described above except with an elevated
temperature condition. Animals were pseudo-randomly assigned to one of two
temperature conditions: ambient or heat. Animals in the ambient condition stayed at a
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constant ambient temperature of 22-23°C throughout the injection time. Animals in the
heat condition stayed at an elevated temperature of 27-30°C throughout all injections
by use of a heating pad placed under the cage monitored by a thermometer placed in
the cage.
Western Blots
Tissue samples thawed on ice and were homogenized in RIPA buffer using a
rotor and pestles. Samples were centrifuged at 12,000g for 20 minutes. The
supernantant was aliquoted into Eppendorf tubes and stored at -80°C. Each sample
underwent a bicinchoninic acid protein concentration assay (Pierce, Rockford, IL)
followed by western blot. Following heat denaturing, samples were loaded into 12%
polyacrylamide gels with 10µg protein per lane. Samples were transferred to PVDF
membranes and blocked for 3 hours in 5% milk in Tris-buffered saline (TBS). Membranes
were washed 3 x 5 minutes and incubated in primary antibody for β-actin anti-mouse
(1:30,000; Proteintech), dopamine transporter anti-goat – DAT (1: 1,000; Santa Cruz),
and tyrosine hydroxylase anti-mouse – TH (1:1,000; Millipore) in 5% milk in Tris-buffered
saline with Tween 20 (TBST) over night. Membranes were washed 3 x 10 minutes in
TBST followed by IR-Dye secondary anti-bodies, goat or mouse (1:5,000; Li-Cor)
incubation in 5% milk in TBST for 1 hour. Membranes were washed 3 x 10 minutes in
TBS and imaged by use of an Odyssey imager. Fluorescent signals are directly
proportional to the amount of the target protein. These values were normalized to βactin and reported as percentage of control group (control-saline animals).
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Data Analysis
For experiment one rectal temperature data were analyzed using two mixed
model ANOVAs with between subjects variables as condition (separated x control) and
drug (saline x meth) and within subjects variable as time (baseline, 1 hour, 3 hours, 5
hours, 7 hours). Separate ANOVAs were run for males and females. For preliminary
experiment two, rectal temperature data were analyzed using two-mixed model
ANOVAs with between subjects variables as condition (separated x control), drug (saline
x meth), and temperature (ambient x heat) and within subjects variable as time
(baseline, 1 hour, 3 hours, 5 hours, 7 hours). Western blotting data were analyzed by
use of the Odyssey imaging program. Fluorescent intensity for each band was
normalized to β-actin and reported as percentage of control (control-saline males or
control-saline females). For experiment one, data were run through a 2x2 betweensubjects ANOVA with between-subjects factors as: condition (separated x control) and
drug (saline x METH). Two separate ANOVAs were run for dopamine transporter and
tyrosine hydroxylase. For the preliminary experiment two, data were analyzed using the
Aligned Rank Transform (Wobbrock et al. 2011). This approach allows for factorial analysis

of nonparametric data, including interactions between factors, by first applying a
transform that aligns data for each effect, then ranking the data points. The aligned rank
data are then subjected to a factorial ANOVA. Significant interaction effects were
followed up with simple effects analysis, and significant dose effects were followed by
Fisher’s least significant difference post hoc tests. Significance was set at α=0.05.
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CHAPTER VIII
RESULTS

Experiment 1
Body Weight
A repeated-measures ANOVA was run for body weights during the first two
weeks with the within subjects factor as day and the between subjects factors as
condition (control x separated) and sex (male x female). There was a significant effect of
day (F12,360=1,568, p<0.001) with weight increasing over the first two weeks, and no
significant effects of condition, sex, or significant interaction (figure 1). Error bars
represent standard error.
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Rectal Temperature
Two repeated-measures ANOVAs were run for males and females for
temperature during drug administration. The within-subjects factor was time (1, 2, 3, 4,
5) and the between-subjects factors were condition (control x separated) and drug
(saline x meth). For males, there was a significant effect of time (F4,80 = 27.13, p<0.001),
a significant time x drug interaction (F4,80 = 5.48, p<0.001) and no other significant
within-subjects effects. There was a significant effect of drug (F1,83 = 15.09, p<0.001)
with methamphetamine increasing rectal temperature. There were no significant effects
of condition or a condition x drug interaction (figure 2). For females, there was a
significant effect of time (F4,66 = 17.86, p<0.001) and no other significant within-subjects
interactions. There were no significant between-subjects effects of condition or drug
(figure 3). All error bars represent standard error.

Figure 2: Temperature Males Exp. 1
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Figure 3: Temperature Females Exp. 1
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Western Blotting
For DAT levels, two separate 2 x 2 between-subjects ANOVAs were run for males
and females, and the same was run for TH levels. Between-subjects factors were
condition (control x saline) and drug (saline x meth). For DAT in males, there was a
significant effect of drug (F1,40 = 32, p<0.01), condition (F1,40 = 9.08, p<0.01), and
condition x drug interaction (F1,40 = 8.4, p<0.01). A test of simple effects revealed that
the effect of drug on DAT levels was significant for separated animals (F1,37 = 36.8,
p<0.01) but not for control animals (F1,37 = 3.63, p>0.05) (figure 4). For females, there
was no significant effect of drug, condition, or a drug x condition interaction (figure 5).
For TH in males, there was a significant effect of drug (F1,44 = 7.18, p<0.05) with
methamphetamine decreasing TH. There were no significant effects of condition or a
drug x condition interaction (figure 6). For TH in females, there were no significant
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effects of drug, condition, or drug x condition interaction (figure 7). All error bars
represent standard error.

Figure 4: DAT in Striatum Males Exp. 1
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Figure 5: DAT in Striatum Females Exp. 1
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Figure 6: TH in Striatum Males Exp. 1
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Figure 7: TH in Striatum Females Exp. 1
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Experiment 2
Body Weight
A repeated-measures ANOVA was run for body weights during the first two
weeks with the within subjects factor as day and the between subjects factors as
condition (control x separated) and sex (male x female). There was a significant effect of
condition, with weight being higher in separated animals (F1,65=8.9, p<.01) (figure 8).
Body weights did not differ at time of testing. Error bars represent standard error.

49

Grams

Figure 8: Body Weights Exp.2
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Rectal Temperature
Two repeated-measures ANOVAs were run for males and females for rectal
temperature during drug administration. The within-subjects factor was time (1, 2, 3, 4,
5) and the between-subjects factors were condition (control x separated), drug (saline x
meth), and temperature (heat x ambient). For males, there was a significant effect of
time (F4,17 = 6.35, p<0.01) and a significant time x drug interaction (F4,17 = 4.9, p<0.01)
and no other significant within-subjects interactions. For between-subjects effects,
there was a significant effect of drug (F1,20 = 9.66, p<0.01), with meth increasing core
temperature and a significant condition x drug interaction (F1,20 = 4.51, p<0.05). There
were no significant effects of condition, temperature, or other significant interactions
(figure 9). For females, there was a significant effect of time (F4,23 = 12.01, p<0.01), a
significant time x drug interaction (F4,23 = 4.08, p<0.01), a significant time x temperature
interaction (F4,23 = 3.72, p<0.05), and a significant time x drug x temperature interaction
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(F4,23 = 2.91, p<0.05). Only females maintained at elevated temperature (heat) showed
elevated core body temperature at times 3, 4, and 5. There were no other significant
within-subjects interactions. For between-subjects effects, there was a significant effect
of drug (F1,27 = 11.63, p<0.01), with meth increasing core temperature, a significant
effect of temperature (F1,27 = 14.77, p<0.01) and a significant drug x temperature
interaction (F1,27 = 5.56, p<0.05). There were no significant effects of condition or other
significant interactions (Figure 10). All error bars represent standard error.

Figure 9: Temperature Males Exp. 2
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Figure 10: Temperature Females Exp. 2
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Western Blotting
For DAT levels, values were transformed using the aligned-rank approach
followed by two separate 2 x 2 x 2 between-subjects ANOVAs for males and females,
and the same was run for TH levels. Between-subjects factors were condition (control x
saline), drug (saline x meth), and temperature (ambient x heat). For DAT in males, there
was a significant effect of drug (F1,24 = 12.11, p<0.01) with meth decreasing DAT levels
and a significant effect of temperature (F1,24 = 10.48, p<0.01) there was no significant
effect of condition or significant interactions (figure 11). For DAT in females, there was a
significant effect of drug (F1,23 =15.1, p<0.01) and temperature (F1,23 =10.88, p<0.01)
and a drug x temperature interaction (F1,23 =16.16, p<0.05) with meth decreasing DAT
levels in the heat condition. There was no significant effect of condition or other
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significant interactions (figure 12). For TH in males, there was a significant effect of
condition (F1,24 = 4.85, p<0.01) and drug (F1,20 = 13.8, p<0.01) with methamphetamine
decreasing TH levels mainly in separated animals and no other significant effects or
interactions (figure 13). For TH in females, there were no significant main effects or
interactions (figure 14). All error bars represent standard error.

Figure 11: DAT in Striatum Males Exp. 2
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Figure 12: DAT in Striatum Females Exp. 2
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Figure 13: TH in Striatum Males Exp. 2
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Figure 14: TH in Striatum Females Exp. 2
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CHAPTER IX
DISCUSSION
The current research examined the effects of early life stress on
methamphetamine induced damage in the striatum. The key findings were as follows: 1.
Decreased dopamine markers occurred in males after methamphetamine
administration. 2. Overall male separated animals exhibited a greater reduction in
methamphetamine induced dopamine transporters relative to controls 3. Females
exhibited decreased markers of dopamine when exposed to both methamphetamine
and elevated temperatures, relative to methamphetamine alone.
The most prominent effects occurred in males. Males exhibited the greatest
reduction in dopamine transporters seven days after methamphetamine administration,
and heat potentiated this reduction in control males. DAT levels in separated males that
received methamphetamine stayed at the same reduced level regardless of
temperature. A similar pattern was observed in TH levels. The largest reduction in TH
levels occurred in separated males, but control males had to be in the elevated
temperature condition to reach about a twenty percent change in TH levels. Tissue was
taken seven days after methamphetamine dosing, suggesting these levels remain stable
and are not a result of acute down-regulation or sequestration after the
methamphetamine binge. Because both DAT and TH levels exhibited the largest decline
in separated animals, these animals may be more susceptible to the effects of
methamphetamine striatal damage relative to control animals.

56

Damage to striatal dopamine neurons leads to several behavioral effects.
Decreased striatal dopamine leads to motor deficits, cognitive impairments, and
possible psychosis. However, these effects occur within disease states such as
Parkinson’s disease and schizophrenia. Few animal studies indicate a direct effect of
methamphetamine binge dosing on behavior. Binges of methamphetamine decrease
recognition memory performance in rats one week, but not seven weeks after dosing
(Belcher, Feinstein, O’Dell, & Marshall, 2008; Clemens, Cornish, Hunt, & McGregor,
2006). Methamphetamine binge-dosing also results in elevated stereotypy and
decreased social interactions, but no alterations in the forced swim task (Clemens,
Cornish, Hunt, & McGregor, 2006). Although few animal studies have addressed the
behavioral and cognitive deficits associated with methamphetamine-induced dopamine
damage, human studies do indicate multiple deficits associated with long-term
methamphetamine abuse (Volkow et al., 2001a; Volkow et al., 2001b). Future studies
need to address the behavioral effects of methamphetamine dosing regimens that
reduce dopaminergic terminal markers. Additionally, many methamphetamine-induced
deficits in humans occur in complex cognitive measurements, whereas there are not
adequate ways to quantify these deficits in animal research.
Although behavior was not quantified in these studies, our results indicate early
life stress may increase vulnerability to methamphetamine induced striatal dopamine
damage in males. Differences in dopamine systems between separated and nonseparated rats may underlie this effect. Separated males exhibit decreased dopamine
transporters in the nucleus accumbens core and caudate-putamen (striatum) relative to
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controls (Brake et al., 2004). Neonatally isolated rats also exhibit increased dopamine
release in the nucleus accumbens after an acute amphetamine injection (Kehoe et al.,
2004). Methamphetamine reverses transport of the dopamine transporter, leading to
elevated extracellular dopamine. Excess dopamine can auto-oxidize, contributing to the
production of reactive oxygen species and terminal damage. Separated animals release
more dopamine, leading to elevated levels in the extracellular space. In addition to
fewer reuptake sites, dopamine likely accumulates in the synaptic cleft leading to
increased methamphetamine induced damage in separated males. However, other
variables cannot be ruled out at this point in time. Overall, the data presented here
suggests early life stress likely potentiates methamphetamine-induced decreases in
dopamine markers.
Previous studies additionally indicate early life stress alters behavioral effects of
psychostimulants. Maternally separated males obtain cocaine, amphetamine, and
methamphetamine self-administration more readily compared to controls, indicating an
increased sensitivity to drug reward (Der-Avakian & Markou, 2010; Lewis et al., 2013;
Moffet et al., 2006). Additionally, separated animals self-administer more cocaine and
methamphetamine relative to controls, suggesting early life stress escalates drug taking
behavior (Lewis et al., 2013; Moffet et al., 2006). Separated animals exhibit increased
locomotor activating effects of methamphetamine compared to control animals
(Pritchard, Hensleigh, & Lynch, 2012). However, separation may (Dimatelis et al., 2012)
or may not (Faure et al., 2005) influence methamphetamine conditioned place
preference reward. Although there are no direct studies, it does appear sensitivity to
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psychostimulant locomotor activity likely predicts psychostimulant induced
monoaminergic damage. Neurotoxic dosing of amphetamines causes mice to become
more sensitive to the locomotor activating effects of amphetamines (Itzhak, AchatMendes, Ali, & Anderson, 2004). Additionally, repeated doses of d-amphetamine
sensitize mice to the locomotor activating effects of various amphetamines and
decreases brain serotonin levels, however, methamphetamine was not tested
(McMillen, Scott, & Williams, 1991). These findings suggest repeated psychostimulant
exposure increases locomotor sensitization and, at high enough doses these drugs can
cause monoaminergic damages. Finally, early life stress increases sensitivity to
psychostimulant reward and locomotor sensitivity. These effects likely share common
mechanisms with systems susceptible to psychostimulant neural damage.
Clinical evidence further supports the role of stress affecting sensitivity to
psychostimulants. The current studies indicated early life stress increases
methamphetamine-induced dopamine damage in the striatum in males. Although there
are no direct clinical studies indicating early life stressors directly relate to increased
drug-induced damage, several studies indicate stress systems highly overlap with
systems affected by methamphetamine. Individuals with a history of life stress are more
likely to develop a substance use disorder (Dube et al., 2004). In chronic
methamphetamine users, stressors increase craving and increase risk of relapse (King et
al., 2010; Soderpalm, Nikolayev, & de Wit, 2003). In addition to behavioral relationships,
several stress pathways and mechanisms of methamphetamine damage overlap.
Methamphetamine dosing can lead to oxidative stress, increased glutamate release, and
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mitochondrial dysfunction. Similarly, chronic stress can lead to the production of
reactive oxygen species, increased glutamate release in areas of the striatum and
cortex, and may contribute to dysfunction of mitochondria. Chronic stress also
potentiates methamphetamine induced hyperthermia (reviewed in Tata & Yamamoto,
2007). Although these effects have not been directly observed in humans, the large
amount of animal research suggests stress alters sensitivity to psychostimulants and
chronic stress contributes to methamphetamine induced dopamine damage.
The effects of chronic methamphetamine use on dopaminergic terminals have
also been documented in human subjects. Humans who met criteria for
methamphetamine substance dependence exhibit decreased dopamine transporters,
dopamine, and tyrosine hydroxylase in the caudate-putamen and nucleus accumbens
(Wilson et al., 1996). Individuals who met the criteria for methamphetamine
dependence additionally show decreased D2 receptors, DAT levels, and decreased
metabolism in the frontal cortex. The extent of damage additionally correlates with
declines in cognitive functioning, indicating methamphetamine causes long-term
decreases in brain functioning, and these effects correlate with cognition (Volkow et al.,
2001a; Volkow et al., 2001b). Humans also exhibit several markers of
methamphetamine-induced cellular damage including increased oxidation levels in the
caudate nucleus and prefrontal cortex (Fitzmaurice et al., 2006). Additionally,
methamphetamine substance abusers exhibit low cellular integrity in the frontal cortex
and basal ganglia as measured by MRS which correlates to cognitive decline (Ernst et al.,
2000; Sekine et al., 2002). These findings indicate methamphetamine causes several
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long-term impairments to neural systems and these impairments highly relate to
cognitive impairments.
Unlike males, separation did not affect methamphetamine-induced depletions in
females. Several studies show early life stress increases sensitivity to psychostimulant
drugs, however, the majority of these studies were only performed in males (DerAvakian & Markou, 2010; Lewis et al., 2013; Moffet et al., 2006). Separated females do
show some potentiated effects of psychostimulants such as increased locomotor
response to an acute injection of methamphetamine relative to males (Pritchard,
Hensleigh, & Lynch, 2012). However, the effects of maternal separation on neural
responses to psychostimulants in females remain largely uncharacterized.
In the current studies, females did not exhibit methamphetamine-induced
reductions in DAT or TH levels, this being a different pattern than that observed in
males. This may be a result of relatively long-lasting effects of methamphetamine in
females. Females exhibit decreased striatal dopamine and dopamine transporters one
day after a bolus (40mg/kg) dose of methamphetamine, the same as their male
counterparts. However, three days after the same dose, males continue to exhibit
decreased striatal DAT levels whereas female levels begin to recover (Bourque, Dluzen,
& Di Paolo, 2012; Dluzen et. al, 2010). Additionally, a greater DAT depletion occurs in
male mice relative to females seven days after 20 or 40 mg/kg methamphetamine
injection (Bourque et al., 2010). Unlike our studies, these studies still found a decrease
in DAT in females seven days after methamphetamine dosing, however, mice were
given methamphetamine in one bolus dose, rather than over the course of eight hours
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which may have caused a greater decrease in dopamine markers. Importantly, these
studies indicate females exhibit an acute decrease in dopamine transporters, but these
levels recover after three days, which does not occur in males. These findings indicate
the effects of methamphetamine on dopamine transporters in females are relatively
short-lived whereas the effects in males remain fairly stable. This may result from a
sequestration or down-regulation of DAT in females but a degeneration effect on
dopamine terminals in males.
However, evidence from the current studies and others suggest that
methamphetamine might affect females more chronically under high temperatures. It is
well documented that elevated temperature potentiates striatal damage caused by
methamphetamine. Males exhibit methamphetamine-induced core body temperature
elevation when given a binge regimen (current studies) or a bolus dose of
methamphetamine (Dluzen, McDermott, & Darvesh, 2010). Further evidence comes
from experiment two, which indicates females core body temperature increased after
methamphetamine injections but only under elevated temperature conditions. Females
in the elevated temperature conditions also exhibited decreased DAT levels, whereas
those in the ambient temperature condition did not. This suggests that females’ ability
to maintain a lower core temperature after methamphetamine injections relative to
males may aid in preventing the long-term decreases in striatal DAT levels. However,
given the small sample size and preliminary nature of these data, further studies are
needed to confirm.
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Variables other than temperature likely contribute to the differences between
males and females. Females show several differences in dopamine systems relative to
males. Males also show decreased dopamine transporters in the striatum relative to
females, and males show a decreased rate of dopamine reuptake relative to females
(Bhatt & Dluzen, 2005; Morissette & Paolo, 1993; Walker et al., 2000). This suggests
females exhibit an increased ability to sequester dopamine. Additionally, males exhibit
heightened dopamine release in the striatum after methamphetamine administration
(Kunnathur et al., 2006). This indicates, relative to females, males have heightened
dopamine release in response to methamphetamine and an impaired ability to decrease
the extracellular amount of dopamine. Elevated dopamine levels lead to reactive oxygen
species and sequestrations of DAT which likely explains the initial decrease in DAT.
Sequestration of DAT only lasts for one to three days after methamphetamine dosing,
suggesting the decreased DAT observed in males are chronic reductions rather than
acute (Fleckenstein et al., 1997).
Other differences may also play a role in the variations between males and
females. Gonadal hormones likely play a role in methamphetamine-induced dopamine
damage. Females exhibit about a 40% reduction in dopamine compared to about a 75%
reduction in males when given 10 mg/kg x 4 dosing pattern of methamphetamine.
These levels remained constant regardless of intact ovaries, indicating hormones might
not play a role (Yu & Wagner, 1994). However, estrogens protect against dopamine
damage in female mice when administered exogenously and females exhibit greater
methamphetamine-induced dopamine depletions when estrogen levels are low during
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diestrus (D’Astrous et al., 2005; Yu & Liao, 2000). These studies indicate estrogen may
play a protective role in methamphetamine induced dopamine damage. Hormones and
estrous cycle were not quantified in the two studies presented here, however, so we
cannot draw any conclusions on the role of hormones.
Human populations exhibit similar sex effects as those observed in animal
models. Similar to animal studies, women exhibit increased methamphetamine-induced
behavioral effects relative to males (Liu & Dluzen, 2007). Women additionally show a
decreased amphetamine-induced dopamine release in the striatum relative to males
(Munro et al., 2006). Although no clinical studies directly indicated methamphetamine
damage is greater in males relative to females, preclinical studies suggest this is highly
likely given the increased dopamine released caused by amphetamines. Additionally,
disorders involving deficits in dopamine functioning, such as Parkinson’s disease,
Huntington’s disease, and schizophrenia, occur more frequently in men than in women
(Scott et al., 2000; Tamir et al., 1969; Aleman et al., 2003). Although we cannot be
certain methamphetamine causes a higher likelihood of dopamine damage in men
relative to women, the preclinical data tells a rather compelling story. Preclinical
evidence will hopefully lead the way for future human studies and possible genderspecific therapeutic approaches.
Clinical research regarding the effects of early life stress or chronic stress on
dopamine terminal damage remains nonexistent. However, human studies indicate
several effects of stress on dopamine system functioning. Children who have been
neglected or abused show lower fMRI activity in areas of the basal ganglia in response
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to natural reward (Dillon et al., 2009; Mehta et al., 2010). Furthermore, individuals with
lower maternal care as children exhibit increased stress-induced dopamine release in
the striatum (Pruessner et al., 2004). Finally, adults with histories of childhood stress
exhibit a greater release of dopamine in the striatum after given an injection of
amphetamine (Oswald et al., 2013). These studies suggest early life stress effects
dopamine functioning and increase amphetamine-induced dopamine release. However,
future studies will need to further evaluate the role of early life stress in
methamphetamine-induced neural damage.
The current studies have many implications for clinical research. The results of
the current studies indicate early life stress may potentiate methamphetamine-induced
neurodegenerative effects, specifically in males. Particularly, individuals exposed to
childhood abuse or neglect have an increased likelihood of developing a substance
abuse disorder and, based on the current results, also have an increased likelihood of
psychostimulant-induced damage to dopamine systems. Future studies will need to
further elucidate these effects in human subjects. Additionally, these findings emphasize
the importance of identifying at-risk populations to develop early interventions.
In conclusion, these were the first studies of the effects of early life stress and
sex on methamphetamine-induced striatal dopamine damage. The results suggest early
life stress may increase methamphetamine induced dopamine transporter loss in males.
Additionally, females do not exhibit an effect of early life stress but did exhibit
methamphetamine induced dopamine transporter decreases but only under elevated
temperature conditions.
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Limitations & Future Directions
The two studies used dopamine transporters and tyrosine hydroxylase levels as a
measure of methamphetamine-induced damage. Binge-dosing patterns of
methamphetamine, such as the regimen used in these two studies, result in damage to
dopamine terminals and cell structure. Similar dosing patterns result in decreased levels
of terminal markers such as: dopamine transporters, tyrosine hydroxylase, and
dopamine receptors, which remain decreased for seven days up to seven years (Gibb &
Korgan, 1979; Seiden, Commins, Vosmer, Axt, & Marek, 1988; Wagner et al., 1980).
These markers may briefly change during the first 1-3 days after methamphetamine
cessation; however, after seven days these depletions remain fairly stable (Ricaurte et
al., 1982). Other studies indicate these reductions occur in conjunction with several
other markers of damaged terminals. Rats given four doses of 4.0mg/kg
methamphetamine over eight hours exhibit axon terminal degeneration in the striatum
by use of silver staining techniques, indicating even low doses of methamphetamine can
lead to terminal damage (Ellison & Switzer, 1993). Additionally, dosage patterns as low
as fours doses of 3.0mg/kg to 10.0mg/kg every two hours cause microglial activation
and increased striatal terminal damage at elevated temperatures (Bowyer et al., 1994;
Broening, Pu, & Vorhees, 1997). Clinical studies also support these findings. Individuals
with a history of chronic methamphetamine use exhibit decreased gray matter in areas
of the limbic system, cingulate cortex, and hippocampus as well as decreased integrity
of white matter tracts throughout areas of the corpus calossum and striatum.
Importantly, these deficits correlated highly with the frequency and duration of drug
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use and performance in several cognitive tasks (Ernst et al., 2000; Thompson et al.,
2004). Although we cannot fully conclude from these studies the presence of
methamphetamine-induced striatal damage, previous studies strongly suggest that
decreased dopamine transporters seven days after methamphetamine cessation are a
hallmark for long-lasting terminal damage caused by a dose-binge pattern of
methamphetamine.
Future studies should address these issues in depth by looking more closely at
markers in human populations and animal studies. Specifically, it will be important to
examine markers of synaptic integrity by utilizing techniques such as fluoro-jade staining
to determine the long-lasting cellular effects of methamphetamine administration and
the correlation with dopamine transporter and tyrosine hydroxylase levels. Other
markers should additionally be characterized such as DOPA decarboxylase or vesicular
monoamine transporters to help determine whether the alterations observed in the
current studies were a result of increased terminal degeneration or a long-term downregulation of transporters. Additionally, several behavioral tasks should be considered
to investigate whether these changes result in long-term behavioral alterations.
Specifically, there are few studies that examine the behavioral effects of chronic
methamphetamine administration in animals. Of these studies, the largest behavioral
deficit is decreased social interaction. One problem likely lies with behavioral assays
which are not sensitive enough to detect cognitive changes. Deficits are observed in
human subjects, but we do not have rodent equivalents to complex measurements such
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as the Wisconsin card sorting task. Future studies should look at developing more
sensitive measurements of cognitive functioning in animals.
Although these studies indicate methamphetamine-induced deficits in dopamine
systems in separated males and females at elevated temperatures, they lack a
mechanism to explain the results. The above discussion posed many reasons for the
early life stress effect and the sex differences. However, future studies should better
elucidate how early life stress alters vulnerability to methamphetamine damage and
why this tends to be specific to males.
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APPENDIX

Diagram of neurotoxic mechanisms of methamphetamine. Black arrows indicate a
causal relationship; red arrows indicate there may not be a direct relationship.
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